Bayer Entered into an Exclusive License Agreement with Cedilla Therapeutics to Develop and Commercialize CyclinE1/CDK2 Complex Inhibitors
- Cedilla will receive an up front and is also eligible to receive development and commercial-based milestones along with royalties on medicines based on the technology commercialized by Bayer
- Bayer to get the full rights on the development and commercialization of Cedilla’s CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers & progressing Cedilla’s programs along with focusing on assets to provide better patient selection
- Additionally, the collaboration strengthens Bayer’s early pipeline in precision oncology & accelerating the research and development of novel cancer therapies
Ref: Bayer | Image: Bayer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.